+ Watch PRTA
on My Watchlist
Prothena has a healthy market cap of 450M despite a very immature pipeline and a questionable therapeutic platform. The company purports to treat amyloidosis and Parkinson's disease with monoclonal antibodies against abnormally folded proteins, but there is no clear evidence that those proteins are the causative agents of disease or simply an irrelevant byproduct. Elan bought the pipeline with their acquisition of Athena Neurosciences in 1996, but it doesn't appear they had much interest in developing it until they spun the division off as Prothena last December. The company quickly went back to the capital markets with a 73M dilutive financing this month, and Janssen sold 2.4M of their own shares alongisde the dilution. Not a major vote of confidence from big pharma. The presence of Baker Brothers with 370K shares tells me that much of the catalyst-free rise from 6 to 21 this year is related to a follower effect. Investors will likely have to wait until 2015 for anything more exciting than phase I safety data.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions